Test na hepatitídu D z krvi: výsledky, načasovanie a ďalšie kroky

Kategórie
Články
Zdravie pečene Interpretácia laboratórnych výsledkov Aktualizácia 2026 Pre pacientov zrozumiteľné

Hepatitis D testing is a two-step process that starts with an antibody screen and ends with HDV RNA confirmation. The crucial point is simple: anyone with hepatitis B surface antigen positivity should discuss HDV testing with their clinician.

📖 ~11 minút 📅
📝 Publikované: 🩺 Odborne medicínsky revidované: ✅ Podložené dôkazmi
⚡ Rýchle zhrnutie v1.0 —
  1. Who needs testing: EASL recommends at least one anti-HDV test for every person with positive hepatitis B surface antigen (HBsAg).
  2. HDV antibody test: A positive anti-HDV result shows exposure to hepatitis D but does not prove current infection.
  3. HDV RNA test: Detectable HDV RNA confirms active viral replication and establishes hepatitis D diagnosis in an HBsAg-positive person.
  4. Negative antibody result: A negative anti-HDV test usually rules out past or current HDV, although RNA testing may still be sensible after a very recent high-risk exposure.
  5. Načasovanie: HDV RNA can become detectable before antibodies, so an early negative antibody result should be repeated when clinical suspicion remains high.
  6. No universal viral-load cutoff: Any confirmed detectable HDV RNA matters; viral-load values in IU/mL are mainly used to follow change over time.
  7. Liver assessment: ALT, AST, bilirubin, platelet count, INR, albumin, fibrosis assessment and ultrasound help determine urgency after a positive RNA result.
  8. Naliehavé príznaky: Yellowing of the eyes, confusion, new abdominal swelling, black stools, or severe vomiting require urgent medical assessment.

The two-step hepatitis D testing sequence

Hepatitis D diagnosis requires an HDV antibody test followed by an HDV RNA test when the antibody screen is positive. HDV cannot establish infection without hepatitis B surface antigen, so the practical starting point is confirming that HBsAg is present.

Hepatitis D blood test pathway represented by laboratory samples and molecular assay equipment
Obrázok 1: A two-stage laboratory pathway separates exposure screening from active-virus confirmation.

Ten/Tá/To anti-HDV antibody assay detects immune recognition of hepatitis D virus. A reactive result means the immune system has encountered HDV at some point, but it cannot distinguish resolved exposure from active infection. The next order is HDV RNA by a sensitive PCR-based molecular assay; detectable RNA confirms current viraemia.

In clinic, I have seen patients incorrectly reassured by an antibody result marked positive but never followed with RNA. That gap matters because HDV is associated with faster fibrosis progression than hepatitis B alone. A positive antibody is a signal to finish the work-up, not the final diagnosis.

Kantesti je Analyzátor krvných testov s umelou inteligenciou that places a reported anti-HDV result beside HBsAg, ALT, AST, bilirubin and platelets, while clearly flagging that it cannot substitute for confirmatory HDV RNA testing. For the surrounding liver markers, our sprievodca pečeňovým panelom explains why a normal-looking single enzyme does not settle the question.

Who should have a hepatitis D blood test?

Every person with confirmed HBsAg positivity should be offered anti-HDV testing at least once, regardless of ALT level or symptoms. This universal approach avoids relying on risk histories that are often incomplete or never recorded.

Hepatitis D blood test eligibility consultation with hepatitis B laboratory results under review
Obrázok 2: Clinicians should offer HDV screening whenever hepatitis B surface antigen is present.

The 2023 EASL hepatitis delta guideline recommends screening all HBsAg-positive people for anti-HDV, then testing HDV RNA if antibodies are detected (EASL, 2023). This includes people with long-standing hepatitis B, newly identified hepatitis B, normal ALT, pregnancy, and people who believe their infection is inactive.

Testing is especially time-sensitive after injection-drug equipment sharing, sex with a person known to have HBV or HDV, dialysis exposure, migration from a high-prevalence setting, or unexplained hepatitis in someone already HBsAg-positive. Stockdale et al. estimated that HDV affects roughly 12 million people globally, although country-level prevalence varies substantially (Stockdale et al., 2020).

A 37-year-old patient I reviewed had HBsAg positivity for 11 years and ALT values between 28 and 46 U/L; anti-HDV was never requested because he felt well. His later RNA result was detectable. Silent liver disease is why hepatitis B symptoms without jaundice deserve attention rather than reassurance.

What a positive or negative HDV antibody result means

A positive HDV antibody test indicates exposure to hepatitis D, while a negative test usually excludes exposure in an established infection. Neither result measures how much virus is currently present.

HDV antibody test concept showing immune proteins interacting with hepatitis D viral particles
Obrázok 3: Antibody screening detects immune exposure rather than active viral replication.

Most laboratories report total anti-HDV as reactive or non-reactive rather than a meaningful numerical concentration. Reactive anti-HDV plus detectable HDV RNA means active hepatitis D. Reactive anti-HDV with undetectable RNA can reflect past cleared infection, intermittent viraemia, an assay near its detection limit, or a specimen and assay issue.

A negative anti-HDV test is reassuring when exposure was remote and there is no acute hepatitis. It is less decisive in the first weeks after a plausible exposure, because RNA may precede a measurable antibody response. In that situation, clinicians commonly repeat anti-HDV and add RNA rather than treating one early negative result as final.

Do not confuse anti-HDV with hepatitis B antibodies. Anti-HBs protects against HBV acquisition, whereas anti-HDV is an exposure marker and does not establish immunity. Our explainer on pozitívnych výsledkov protilátok covers why antibody names can be misleading on a report.

HDV RNA test: the result that confirms active infection

A detectable HDV RNA result in an HBsAg-positive person confirms active hepatitis D infection. RNA is the test clinicians use to confirm viraemia, establish a baseline and judge virological response during treatment.

HDV RNA test processing in a molecular laboratory with precision extraction equipment
Obrázok 4: Molecular testing identifies active HDV genetic material in a laboratory specimen.

HDV RNA is generally reported qualitatively as detected or not detected, and often quantitatively in IU/ml or log10 IU/mL. There is no single international RNA threshold below which active HDV is harmless. A result of 100 IU/mL and a result of 100,000 IU/mL both require specialist interpretation in the context of liver injury and fibrosis.

Assay sensitivity differs. Some specialist laboratories quantify down to roughly 6 to 10 IU/mL, while other assays have a higher lower limit of quantification; the report should state whether RNA was not detected or merely detected below quantification. Repeating testing through the same laboratory makes trends more interpretable.

Kantesti je službe na interpretáciu výsledkov AI laboratórnych testov that can organize longitudinal ALT, bilirubin, platelet and HDV RNA entries for a hepatology appointment, but it does not diagnose infection from an image alone. If one report seems inconsistent with another, use a sprievodca zmenou výsledkov z krvného testu before assuming the virus has changed.

When to test after a possible exposure

Testing after a possible HDV exposure should start promptly if HBsAg is positive, with repeat antibody and RNA testing when the first tests occur early. There is no reliable one-day window that guarantees exclusion after a recent exposure.

Hepatitis D testing timeline represented by sequential laboratory collection tools and calendar-like arrangement
Obrázok 5: Early molecular testing and later antibody testing answer different timing questions.

HDV RNA may be detectable before anti-HDV antibodies appear, particularly during acute co-infection or superinfection. If an HBsAg-positive person has a recent high-risk event and acute hepatitis symptoms, clinicians often request anti-HDV and RNA together instead of waiting for the screen.

For a first negative screen obtained within weeks of a high-risk event, repeat testing is usually individualized around symptoms, ALT trajectory and the exposure date. In my experience, a repeat at about 6 až 12 týždňov is a practical discussion point, but local specialist advice takes priority because assay access and baseline HBV status change the plan.

New fatigue alone is nonspecific; dark urine, jaundice, right-upper abdominal discomfort and marked nausea make urgent assessment more appropriate. If liver enzymes are fluctuating after lifestyle changes, ALT po úbytku hmotnosti offers useful context, though it should never delay viral testing.

HDV co-infection versus HBV superinfection

HDV co-infection occurs when HBV and HDV are acquired together, whereas superinfection occurs when HDV infects someone with established chronic hepatitis B. Superinfection is more likely to become chronic and can cause a sharper deterioration in liver function.

Hepatitis B and hepatitis D viral interaction shown as paired particles near a liver cell
Obrázok 6: HDV relies on hepatitis B surface antigen to enter and spread.

HDV borrows hepatitis B surface antigen to assemble infectious particles. This biological dependency explains a core rule: a person who is truly HBsAg-negative does not have active hepatitis D, even if a result elsewhere has been confusing. HBV vaccination prevents HDV by preventing HBV infection.

Co-infection can present as acute hepatitis with both HBV markers and HDV RNA changing rapidly. Superinfection may show a sudden ALT rise, deteriorating bilirubin, or liver decompensation in a person previously living with HBV. The distinction affects prognosis, although the immediate laboratory sequence remains anti-HDV followed by RNA confirmation.

Dr. Thomas Klein, MD, has found that the most useful clinical question is often not “How high is the RNA?” but “What was this patient’s HBV and liver baseline six months ago?” Reviewing FIB-4 liver-fibrosis risk can help frame that conversation, but it cannot replace elastography or specialist care.

Which liver tests matter after positive HDV RNA?

Positive HDV RNA warrants a full liver severity assessment: ALT, AST, bilirubin, albumin, INR, platelet count, HBV DNA, kidney function and fibrosis evaluation. These results identify active injury and possible cirrhosis, not simply the presence of virus.

Liver severity assessment combining albumin bilirubin coagulation and platelet laboratory materials
Obrázok 7: Liver injury and synthetic function tests complement HDV RNA confirmation.

ALT and AST reflect hepatocyte injury but can be normal in meaningful chronic liver disease. ALT above approximately 35 U/L u mužov alebo 25 U/L u žien is often considered above a healthy reference threshold in viral-hepatitis guidance, yet each laboratory’s range and the patient’s baseline still matter. Bilirubin above the laboratory upper limit with rising INR deserves faster review.

Počet krvných doštičiek nižší ako 150 × 10⁹/L can be an early clue to portal hypertension in chronic liver disease, particularly alongside splenomegaly or a rising FIB-4 score. Albumin below 35 g/L and INR above 1.2 may indicate impaired hepatic synthetic function, though nutrition, medicines and anticoagulants can confound both.

Kantesti AI interprets liver-test patterns by comparing multiple measurements rather than declaring hepatitis severity from ALT alone. Readers can review varovných príznakov cirhózy a sprievodca vzorcom bilirubínu ešte pred vašou návštevou.

Can hepatitis D be present with normal liver enzymes?

Yes, hepatitis D can be present when ALT and AST are within the laboratory reference interval. Normal enzymes lower the likelihood of brisk current injury, but they do not exclude HDV RNA positivity, fibrosis or future flares.

Comparison of stable and fluctuating liver enzyme patterns beside hepatitis D molecular testing equipment
Obrázok 8: Normal enzymes do not rule out active HDV or accumulated liver scarring.

ALT is a moving signal, not a fibrosis meter. Exercise, muscle injury, fatty liver, alcohol, medication effects and viral activity can all alter it; a single ALT of 31 U/L may be unremarkable for one person and a meaningful increase from a prior baseline of 12 U/L for another.

The reason clinicians worry about HDV RNA combined with low platelets or an elevated liver stiffness result is that the combination can suggest fibrosis despite modest enzymes. Conversely, an isolated mild AST rise after a marathon may be muscular rather than hepatic. Context changes the interpretation.

For people who receive results before their clinician calls, why portals release labs early explains the workflow. Do not start supplements marketed as liver cleanses; several can themselves raise ALT or cause liver injury.

How to prepare for an HDV antibody or RNA test

HDV antibody and HDV RNA tests usually require no fasting, special diet or medication washout. The main preparation is making sure the ordering clinician and laboratory know the patient is HBsAg-positive and need an HDV-specific assay.

Patient preparing laboratory requisition and hepatitis D molecular testing materials before sample collection
Obrázok 9: Clear ordering and correct molecular specimen handling are more important than fasting.

Continue prescribed hepatitis B treatment unless the prescriber gives different instructions. Stopping antivirals before testing can destabilize HBV control and does not improve HDV RNA accuracy. Bring previous HBV DNA, HBsAg, ALT and imaging results where possible, because they establish the clinical timeline.

For molecular testing, sample handling matters more than the patient’s breakfast. A laboratory may require plasma collected and transported under validated conditions; delays, inadequate volume and assay-specific handling can lead to an indeterminate or non-quantifiable result.

Kantesti je Nástroj na analýzu krvných testov poháňaný AI designed to extract results from laboratory PDFs and preserve the units, reference intervals and draw dates that hepatologists need. Our kontrolnom zozname kvality nahrávania PDF is useful when a scanned report has tiny print or multiple language formats.

What discordant hepatitis D test results can mean

Positive anti-HDV with negative RNA is the most common discordant pattern and does not automatically mean the antibody result was wrong. It usually triggers repeat RNA testing, assay review and a full assessment of clinical context.

Discordant HDV antibody and RNA laboratory results represented by paired assay chambers and liver markers
Obrázok 10: Discordant screening and RNA results need repeat testing rather than guesswork.

Anti-HDV positive and RNA negative may represent resolved infection or virus below the test’s limit of detection. Repeat RNA is particularly reasonable when ALT is elevated, fibrosis is present, the first specimen was poorly handled, or the result came from a non-specialist assay with limited sensitivity.

Anti-HDV negative with detectable RNA is uncommon but possible early in infection or with assay limitations. A specialist laboratory may repeat both assays, confirm HBsAg and review whether the reported result actually refers to a different hepatitis marker. Never assume a clerical label is clinically impossible.

One practical safeguard is to compare specimen date, units and assay name rather than comparing only red or green flags. Qualitative versus quantitative tests explains why “not detected” and “below quantification” are not interchangeable.

Monitoring after a confirmed hepatitis D diagnosis

Confirmed HDV RNA requires hepatology or infectious-disease follow-up, with repeat viral, liver-function and fibrosis assessments at intervals tailored to disease severity and treatment. There is no safe universal schedule for every person.

Longitudinal hepatitis D monitoring represented by sequential laboratory specimens and liver imaging model
Obrázok 11: Longitudinal monitoring combines viral activity with fibrosis and liver-function trends.

Monitoring commonly includes HDV RNA, ALT, AST, bilirubin, albumin, INR, platelets and HBV DNA. A repeat interval of 3 až 6 mesiacov is often used during active disease or treatment, while stable patients may be monitored differently by their hepatology team. RNA trends are more meaningful when measured by the same assay.

People with cirrhosis need surveillance beyond routine blood work. Ultrasound-based hepatocellular carcinoma surveillance is commonly performed every 6 mesiacov, and new ascites, confusion, gastrointestinal bleeding or jaundice require same-day medical assessment. Blood tests cannot safely replace imaging in this setting.

Naše sprievodca pozdĺznou laboratórnou analýzou explains what to record after each draw: medication changes, illness, alcohol exposure, fasting status and laboratory location. Those details often explain a one-off change that otherwise looks alarming.

How treatment changes hepatitis D test interpretation

Treatment response is judged by change in HDV RNA together with liver enzymes and clinical status, not by antibody disappearance. Anti-HDV often remains positive long after viraemia has fallen or become undetectable.

Hepatitis D treatment response assessment showing molecular assay and liver marker monitoring setup
Obrázok 12: Treatment follow-up tracks RNA change alongside liver injury and function markers.

A falling HDV RNA level is encouraging, but an undetectable result should be interpreted against the assay’s lower limit and timing. Some patients show fluctuating viraemia, so clinicians usually confirm meaningful changes with repeat measurements rather than making a major decision from one result.

Bulevirtide is available in some jurisdictions for chronic hepatitis D, while access, licensing and treatment pathways vary internationally. Pegylated interferon-based approaches remain relevant in selected settings but require careful monitoring for adverse effects and are not appropriate for everyone.

Ten/Tá/To Kantesti medical validation approach describes why our outputs identify follow-up patterns rather than recommend prescription changes. Medication decisions for HDV should sit with a specialist who knows the patient’s fibrosis stage, HBV treatment and pregnancy plans.

Pregnancy, partners and prevention after HDV testing

A positive HDV result does not change the need to prevent hepatitis B transmission: household and sexual contacts should have documented HBV vaccination or serologic immunity. Pregnancy requires coordinated obstetric and liver-specialist care rather than delayed testing.

Hepatitis D prevention consultation with vaccination documentation and family laboratory planning materials
Obrázok 13: HBV vaccination protects contacts from the hepatitis B dependency required by HDV.

HDV depends on HBV, so hepatitis B vaccination prevents hepatitis D in people who are not already infected with HBV. Contacts can discuss HBsAg, anti-HBs and anti-HBc testing with their clinician; an anti-HBs level of at least 10 mIU/mL after vaccination is generally considered protective in immunocompetent people.

Pregnant people with HBsAg positivity should not be excluded from anti-HDV screening. A positive result warrants specialist planning because liver status, HBV DNA, medication suitability and newborn HBV immunoprophylaxis all need coordinated attention. The evidence around HDV-specific pregnancy management is still thinner than I would like.

For families storing results across several clinicians, our sprievodca rodinným zdravotným záznamom can help preserve dates and consent boundaries. Dr. Thomas Klein, MD, advises bringing a written medication list and prior pregnancy records to the first joint review.

When hepatitis D results need urgent medical attention

Seek urgent care for jaundice, confusion, severe persistent vomiting, fainting, new abdominal swelling, fever with marked illness, or black stools—whether HDV testing is pending or already positive. These symptoms can signal severe hepatitis or liver decompensation.

Urgent liver symptom triage in a calm medical center reception setting with hepatitis test documents
Obrázok 14: Severe liver-related symptoms require prompt clinical assessment beyond laboratory interpretation.

Rapidly rising bilirubin, a prolonged INR, low glucose or new confusion can occur in acute liver failure and need emergency evaluation. A bilirubin result above 50 µmol/l (about 2.9 mg/dL) is not automatically an emergency, but the combination with jaundice, INR elevation or worsening symptoms changes the urgency substantially.

Call the clinician promptly after a new detectable HDV RNA result, even if you feel well. Most positive RNA results do not require an ambulance, but they should not wait for an annual check-up. Bring the complete report, including test method and limit of detection, to the appointment.

Klinický obsah Kantesti je revidovaný s prispením našich Lekárska poradná rada, but our interpretation never replaces urgent assessment. If symptoms suggest decompensation, seek local emergency care rather than uploading another report.

Často kladené otázky

Kto by sa mal nechať otestovať na hepatitídu D?

Každý s pozitívnym výsledkom vyšetrenia povrchového antigénu hepatitídy B by mal mať test na protilátky proti HDV aspoň raz, aj keď je ALT normálna a nie sú žiadne príznaky. Smernica EASL z roku 2023 odporúča univerzálne skríningové vyšetrenie na anti-HDV u osôb s pozitívnym HBsAg, po ktorom nasleduje testovanie HDV RNA v prípade reaktivity protilátok. Testovanie je obzvlášť naliehavé po nedávnom parenterálnom vystavení vírusu, nevysvetliteľnej hepatitíde alebo náhlom zhoršení existujúcej hepatitídy B. Krvný test na hepatitídu D nie je rutinne užitočný u osoby s potvrdeným negatívnym výsledkom HBsAg.

Znamená pozitívny test na protilátky HDV, že mám hepatitídu D?

A positive HDV antibody test means you have been exposed to hepatitis D virus, but it does not by itself prove active infection. Active hepatitis D is confirmed when HDV RNA is detectable in an HBsAg-positive person. Anti-HDV can remain positive after infection has cleared, and RNA can occasionally fluctuate around a laboratory detection limit. Ask for HDV RNA, usually reported as detected or not detected and sometimes in IU/mL, after a reactive antibody result.

Ako dlho trvá, kým sa hepatitída D objaví v krvnom teste?

HDV RNA môže byť detekovateľná skôr ako protilátky proti HDV, takže načasovanie závisí od toho, ktorý test na hepatitídu D z krvi sa používa. Po veľmi nedávnej expozícii môžu lekári spolu objednať protilátky a RNA a zopakovať ich približne o 6 až 12 týždňov, ak sú počiatočné testy negatívne, ale podozrenie zostáva vysoké. Neexistuje žiadny jeden garantovaný deň vylúčenia, pretože individuálna imunita, citlivosť testu a to, či je HBV novo získaná alebo chronická, to všetko ovplyvňuje načasovanie. Akútne príznaky alebo rastúci ALT by mali viesť k lekárskemu posúdeniu bez čakania na opakované stanovenie.

Aká hladina HDV RNA sa považuje za vysokú?

There is no universally accepted HDV RNA cutoff in IU/mL that separates harmless from dangerous infection. Any detectable HDV RNA confirms active viral replication when HBsAg is positive, while serial change in the same assay helps clinicians evaluate disease activity and treatment response. A value of 1,000 IU/mL is therefore not interpreted in isolation from ALT, bilirubin, platelets, fibrosis testing and symptoms. Laboratories may have lower quantification limits around 6 to 10 IU/mL, but methods vary.

Can I have hepatitis D with normal ALT?

Yes, hepatitis D can be present with ALT within the laboratory reference interval. ALT measures current hepatocyte injury imperfectly and can fluctuate; it does not reliably exclude HDV RNA positivity or fibrosis. Clinicians assess ALT alongside AST, bilirubin, albumin, INR, platelet count, HBV DNA and liver stiffness or imaging. An ALT below 35 U/L in men or 25 U/L in women may be reassuring in context, but it does not cancel the need for HDV testing when HBsAg is positive.

Can hepatitis B vaccination prevent hepatitis D?

Yes, hepatitis B vaccination prevents hepatitis D in people who are not already infected with HBV because HDV requires hepatitis B surface antigen to form infectious particles. After a completed hepatitis B vaccine series, an anti-HBs concentration of at least 10 mIU/mL is generally considered protective in immunocompetent adults. Vaccination does not treat existing chronic hepatitis B or hepatitis D, so HBsAg-positive people need specialist testing and follow-up instead. Household and sexual contacts of someone with HBV or HDV should discuss vaccination and serology with their clinician.

Získajte analýzu krvných testov s podporou AI už dnes

Pridajte sa k viac než 2 miliónom používateľov na celom svete, ktorí dôverujú Kantesti pri okamžitej a presnej analýze laboratórnych testov. Nahrajte svoje výsledky krvných testov a získajte komplexnú interpretáciu biomarkerov 15,000+ v priebehu sekúnd.

📚 Citované publikácie výskumu

1

Klein, T., Mitchell, S., & Weber, H. (2026). RDW Blood Test: Complete Guide to RDW-CV, MCV & MCHC. Kantesti LTD. (2026). Zenodo. https://doi.org/10.5281/zenodo.18202598. ResearchGate: https://www.researchgate.net/ Academia.edu: https://www.academia.edu/. Kantesti AI Medical Research.

2

Klein, T., Mitchell, S., & Weber, H. (2026). BUN/Creatinine Ratio Explained: Kidney Function Test Guide. Kantesti LTD. (2026). Zenodo. https://doi.org/10.5281/zenodo.18207872. ResearchGate: https://www.researchgate.net/ Academia.edu: https://www.academia.edu/. Kantesti AI Medical Research.

📖 Externé lekárske referencie

3

European Association for the Study of the Liver (2023). EASL Clinical Practice Guidelines on hepatitis delta virus. Journal of Hepatology.

4

Stockdale AJ et al. (2020). The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. Journal of Hepatology.

2 milióny+Analyzované testy
127+Krajiny
75+Jazyky

⚕️ Vyhlásenie o lekárskej starostlivosti

Signály dôvery E-E-A-T Trust Signals

Skúsenosti

Klinické hodnotenie vedené lekárom pracovných postupov interpretácie laboratórnych výsledkov.

📋

Odbornosť

Laboratórna medicína so zameraním na to, ako sa biomarkery správajú v klinickom kontexte.

👤

Autoritatívnosť

Napísané Dr. Thomasom Kleinom, recenzia Dr. Sarah Mitchell a prof. Dr. Hans Weber.

🛡️

Dôveryhodnosť

Interpretácia založená na dôkazoch s jasnými následnými krokmi na zníženie poplachu.

🏢 Kantesti LTD registrované v Anglicku a vo Walese · Spoločnosť č. 17090423 Londýn, Spojené kráľovstvo · kantesti.net
blank
Od Prof. Dr. Thomas Klein

Dr. Thomas Klein je certifikovaný klinický hematológ a pôsobí ako hlavný lekár (Chief Medical Officer) v Kantesti AI. S viac než 15-ročnou praxou v laboratórnej medicíne a silným záujmom o interpretáciu výsledkov krvných testov podporovanú AI sa snaží prepojiť nové technológie s každodennou klinickou praxou. Jeho oblasti záujmu zahŕňajú analýzu biomarkerov, výskum klinickej podpory rozhodovania a optimalizáciu referenčných intervalov špecifických pre populáciu. Ako CMO poskytuje klinický vstup pre interné benchmarkovanie platformy a zabezpečuje klinický dohľad nad medicínskou kvalitou vzdelávacích správ Kantesti.

Pridaj komentár

Vaša e-mailová adresa nebude zverejnená. Vyžadované polia sú označené *